Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited has launched its Nasodine Nasal Spray, a product aimed at promoting nasal hygiene, in the U.S. market without FDA approval based on its categorization and legal advice. The product is available for purchase online and will be supported by a social media advertising campaign, with plans to eventually distribute it through U.S. pharmacies. This launch marks a significant step for Firebrick as it evolves into a commercial pharmaceutical business with further products expected to join the Nasodine brand in the U.S. market.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
